Image may be NSFW.
Clik here to view.
Shares in Teva Pharmaceutical (NYSE:TEVA) fell slightly in pre-market activity today after the pharmaceutical company beat earnings expectations on Wall Street with its 1st quarter results.
The Israel-based company posted profits of $641 million on sales of $5.63 billion for the 3 months ended March 31, for bottom-line growth of 1.3% on sales growth of 17% compared with the same period last year.
Teva’s sales were boosted by its $40.5 billion acquisition of Allergan‘s (NYSE:AGN) generic drug biz, Actavis, last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Teva beats estimates for Q1 earnings appeared first on MassDevice.
